To explain the role of mifepristone in medical abortions that results in fulminant and lethal septic shock due to Clostridium sordellii.
DATA SOURCES:
MEDLINE, PubMed, and Google Scholar databases were searched (1984–March 2005%). Key search terms were mifepristone, RU38486, RU486, Mifeprex, medical abortion, septic shock, innate immune system, cytokines, and Clostridium sordellii.
STUDY SELECTION AND DATA EXTRACTION:
All articles identified from the data sources were evaluated and all information deemed relevant was included for the information related to the development of the understanding of the pathophysiology of mifepristone-induced septic shock due to C. sordellii.
DATA SYNTHESIS:
The mechanisms of action of mifepristone were incorporated into the pathophysiology of septic shock due to C. sordellii. Mifepristone, by blocking both progesterone and glucocorticoid receptors, interferes with the controlled release and functioning of cortisol and cytokines. Failure of physiologically controlled cortisol and cytokine responses results in an impaired innate immune system that results in disintegration of the body's defense system necessary to prevent the endometrial spread of C. sordellii infection. The abnormal cortisol and cytokine responses due to mifepristone coupled to the release of potent exotoxins and an endotoxin from C. sordellii are the major contributors to the rapid development of lethal septic shock.
CONCLUSIONS:
Theoretically, it appears that the mechanisms of mifepristone action favor the development of infection that leads to septic shock and intensifies the actions of multiple inflammatory cytokines, resulting in fulminant, lethal septic shock.
DonaldsonMSDorflingerLBrownSSBenetLZ. Clinical applications of mifepristone (RU486) and other antiprogestins. Institute of Medicine. Washington, DC: National Academy Press, 1993: 1–120.
2.
BrouckaertPEveraerdtBFiersW. The glucocorticoid antagonist RU38486 mimics interleukin-1 in its sensitization to the lethal and interleukin-6–inducing properties of tumor necrosis factor. Eur J Immunol1992; 22: 981–6.
3.
McGregorJASoperDELovellGToddJK. Maternal deaths associated with Clostridium sordellii infection. Am J Obstet Gynecol1989; 161: 987–95.
4.
BittiAMastrantonioPSpigagliaPIrriGSpanoAIMorettiG, et al. A fatal postpartum Clostridium sordellii associated toxic shock syndrome. J Clin Pathol1997; 50: 259–60.
SinaveCLeTemplierGBlouinDLeveilliFDelandE. Toxic shock syndrome due to Clostridium sordellii: a dramatic postpartum and postabortion disease. Clin Infect Dis2002; 35: 1441–3.
9.
WiebeEGjilbertEFacotFShannonCWinikoffB. A fatal case of Clostridium sordellii septic shock syndrome associated with medical abortion. Obstet Gynecol2004; 104 (5 pt 2 suppl): 1142–4.
10.
Notice of a second report of the same case. Obstet Gynecol2005; 105: 673.
11.
OpalSM. The clinical relevance of sepsis related to gram-positive bacterial pathogens (abstract 258). 6th World Congress on Trauma, Shock, Inflammation and Sepsis—pathophysiology, immune consequences and therapy. Shock2004; 21 (suppl): 65.
12.
VegaVLDeMaioA. Isolated macrophages: an ex vivo paradigm to study the contribution of genetics and environment to the inflammatory response. 6th World Congress on Trauma, Shock, Inflammation and Sepsis—pathophysiology, immune consequences and therapy (abstract 281). Shock2004; 21 (suppl): 71.
13.
GaillardRCRiondelAMullerAFHerrmannWBaulieuEE. RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary–adrenal system at a specific time of day. Proc Natl Acad Sci U S A1984; 81: 3879–82.
14.
HoganSFIrelandK. Fatal acute spontaneous endometritis resulting from Clostridium sordellii. Am J Clin Pathol1989; 91: 104–6. Erratum 1989; 92: 128.
15.
AbdullaAYeeL. The clinical spectrum of Clostridium sordellii bacteraemia: two case reports and a review of the literature. J Clin Pathol2000; 53: 709–12.
AloufJE. Cholesterol-binding cytolytic protein toxins. Int J Med Microbiol2000; 290: 351–6.
19.
Vouret-CraviariVGrallDFlatauGPouyssegurJBoquetPVan Obberghen-SchillingE. Effects of cytotoxic necrotizing factor 1 and lethal toxin on actin cytoskeleton and VE-cadherin localization in human endothelial cell monolayers. Infect Immun1999; 67: 3002–8.
20.
JanewayCJrMedzhitovR. Innate immune recognition. Annu Rev Immunol2002; 20: 197–216.
21.
TriantafilouMTriantafilouK. Receptor cluster formation during activation by bacterial products (abstract 36). 6th World Congress on Trauma, Shock, Inflammation and Sepsis—pathophysiology, immune consequences and therapy. Shock2004; 21 (suppl): 9.
LeonhardtABoonyaratanakornkitVEdwardsD P. Progesterone receptor transcription signaling mechanisms. Steroids2003; 68: 761–70.
24.
OpalSMHuberCE. The role of interleukin-10 in critical illness. Curr Opin Infect Dis2000; 13: 221–6.
25.
EbongllSCallDNemzekJBolgosGNewcombDRemickD. Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immunol1999; 67: 6603–10.
26.
LazarGJrLazarGAgarwalMK. Modification of septic shock in mice by the antiglucocoticoid RU 38486. Circ Shock1992; 36: 180–4.
27.
BairdDT. Mode of action of medical methods of abortion. J Am Med Women's Assoc2000; 55: 121–6.
28.
GaillardRC. Interaction between the hypothalamo–pituitary–adrenal axis and the immunological system. Ann Endocrinol (Paris)2001; 62: 155–63.
29.
WilliamsonDRLapointeM. The hypothalamic–pituitary–adrenal axis and low-dose glucocorticoids in the treatment of septic shock. Pharmacotherapy2003; 23: 514–25.
30.
AnnaneDCavaillonJM. Corticosteroids in sepsis: from bench to bedside?Shock2003; 20: 197–207.
31.
WebsterJISternbergEM. Role of the hypothalamic–pituitary–adrenal axis, glucocorticoids and glucocorticoid receptors in toxic sequelae of exposure to bacterial and viral products. J Endocrinol2004; 181: 207–21.
32.
WebsterJITonelliLSternbergEM. Neuroendocrine regulation of immunity. Annu Rev Immunol2002; 20: 125–63.
YoshimuraALienEInfallsRRTuomanenEDziarskiRGolenbockD. Cutting edge: recognition of gram-positive bacterial cell wall components by the innate immune system occurs via toll-like receptor 2. J Immunol1999; 163: 1–5.
35.
KelsoA. Cytokines: principles and prospects. Immunol Cell Biol1998; 67: 300–17.
36.
SegnitzBGehringU. Mechanism of action of a steroidal antiglucocorticoid in lymphoid cells. J Biol Chem1990; 265: 2789–96.
37.
HawesASRockCSKeoghCVLowrySFCalvanoSE. In vivo effects of the antiglucocorticoid RU 486 on glucocorticoid and cytokine responses to Escherichia coli endotoxin. Infect Immun1992; 60: 2641–7.
38.
SwainMGAppleyardCWallaceJWongHLeT. Endogenous glucocorticoids released during acute toxic liver injury enhance hepatic IL-10 synthesis and release. Am J Physiol Gastrointest Liver Physiol1999; 276: G199–205.
39.
LazarGJrDudaELazarG. Effect of RU38486 on TNF production and toxicity. FEBS Lett1992; 308: 137–40.
40.
GallilyRYaminAWaksmannYOvadiaHWeidenfeldJBar-JosephA, et al. Protection against septic shock and suppression of tumor necrosis factor a and nitric oxide production by dexanabilol (HU-211), a nonpsychotropic cannabinoid. J Pharmacol Exp Ther1997; 283: 918–24.
41.
TraceyKJ. The inflammatory reflex. Nature2002; 420: 853–9.
42.
TreutigerCJMullinsFEJohanssonASMRouhiainenARauvalaHMEErlandsson-HarrisH, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med2003; 254: 375–85.
43.
OpalSMHuberCE. Bench-to-bedside review: toll-like receptors and their role in septic shock. Crit Care2002; 62: 125–36.
44.
AnderssonUWangHPalmbladKAvebergerACBloomOErlandsson-HarrisH, et al. High mobility group 1 (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med2000; 192: 565–70.
45.
WangHBloomOZhangMVishnubhakatJMOmbrellinoMCheJ, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science1999; 285: 248–1.
46.
RiedelmannNCGuoRFWardPA. Novel strategies for the treatment of sepsis. Natl Med2003; 9: 517–24.
47.
MengGRutzMGrabiecMSchwandnerREbelFBuschDH, et al. Prevention of experimental TLR2 driven shock by application of specific inhibitor proteins (abstract 260). 6th World Congress on Trauma, Shock, Inflammation and Sepsis—pathophysiology, immune consequences and therapy. Shock2004; 21 (suppl): 65.
48.
ChuaGKang-HoeL. Marked elevations in N-terminal brain natriuretic peptide levels in septic shock. Crit Care2004; 8: R248–50. Epub 15 Jun 2004, DOI 10.1186/cc2889
49.
DonninoMWRiversEPMcCordJOteroRGoyalNJacobsenG, et al. B-type natriuretic peptide in severe sepsis and septic shock. Acad Emerg Med2005; 12 (suppl 1): 38.
